SUMMARY - Health Canada Drug Approvals
In the quiet hum of a pharmacy in rural Saskatchewan, a pharmacist waits for the arrival of a new biological therapy for a patient with a rare autoimmune condition. The medication has been approved in the United States for eighteen months, yet the local supply remains uncertain due to ongoing regulatory reviews and procurement negotiations. For this patient, the delay is not merely an administrative inconvenience; it is a period of prolonged physical suffering and anxiety, representing the tangible human cost of regulatory caution.